The use of systemic and topical fluoroquinolones

Pediatrics

Volumn 128, Issue 4, 2011, Pages

  Bradley, John S ^a   Jackson, Mary Anne ^a   Brady, Michael T ^a   Bernstein, Henry H ^a   Byington, Carrie L ^a   Edwards, Kathryn M ^a   Fisher, Margaret C ^a   Glode, Mary P ^a   Keyserling, Harry L ^a   Kimberlin, David W ^a   Maldonado, Yvonne A ^a   Orenstein, Walter A ^a   Schutze, Gordon E ^a   Willoughby, Rodney E ^a  

^a NONE

Author keywords

Fluoroquinolones; Infectious diseases; Pediatrics; Systemic therapy

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; BESIFLOXACIN; CEFIXIME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; CLARITHROMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; GATIFLOXACIN; GEMIFLOXACIN; HYDROCORTISONE ACETATE PLUS NEOMYCIN PLUS POLYMYXIN B; LEVOFLOXACIN; MOXIFLOXACIN; NALIDIXIC ACID; NORFLOXACIN; OFLOXACIN; PLACEBO; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ABDOMINAL INFECTION; ACCIDENTAL INJURY; ACHILLES TENDON RUPTURE; ACUTE OTITIS MEDIA; ANTHRAX; ANTIBIOTIC RESISTANCE; ARM PAIN; ARTHRALGIA; ARTHRITIS; ARTHROPATHY; ARTICLE; BACKACHE; BONE DEVELOPMENT; BONE PAIN; CHONDROPATHY; CLINICAL PRACTICE; CONJUNCTIVITIS; CONVULSION; DIZZINESS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG PENETRATION; DRUG SAFETY; DRUG USE; EXTERNAL OTITIS; GAIT DISORDER; GASTROINTESTINAL INFECTION; GRAM NEGATIVE INFECTION; GRAM POSITIVE INFECTION; HEADACHE; HIP PAIN; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSOMNIA; JOINT DESTRUCTION; JOINT HYPERMOBILITY; LEG PAIN; LIMB PAIN; LIVER DYSFUNCTION; MENINGOCOCCOSIS; MOTOR DYSFUNCTION; MULTICENTER STUDY (TOPIC); MULTIDRUG RESISTANT TUBERCULOSIS; MUSCLE HYPERTONIA; MUSCULOSKELETAL DISEASE; MYALGIA; NERVOUSNESS; NIGHTMARE; NONHUMAN; OSTEOARTHRITIS; OTITIS MEDIA; PAIN; PERIPHERAL NEUROPATHY; PHOTOSENSITIVITY; PNEUMONIA; PRESCRIPTION; PRIORITY JOURNAL; PYELONEPHRITIS; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RISK BENEFIT ANALYSIS; SALMONELLOSIS; SCOLIOSIS; SEIZURE; SHIGELLOSIS; SHOULDER PAIN; SIDE EFFECT; SINGLE DRUG DOSE; SINUSITIS; SLEEP DISORDER; SOMNOLENCE; SPINE PAIN; TENDON DISEASE; TRAVELLER DIARRHEA; TREATMENT INDICATION; TUBERCULOSIS; TYMPANOSTOMY TUBE OTORRHEA; TYPHOID FEVER; URINARY TRACT INFECTION; VOMITING; WALKING DIFFICULTY;

ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; HUMANS;

EID: 80053477373     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2011-1496     Document Type: Article

References (69)

1. Tatsumi H, Senda H, Yatera S, Takemoto Y, Yamayoshi M, Ohnishi K. Toxicological studies on pipemidic acid. V. Effect on diarthrodial joints of experimental animals. J Toxicol Sci. 1978;3(4):357-367 (Pubitemid 9117040)
2. Gough A, Barsoum NJ, Mitchell L, McGuire EJ, De la Iglesia FA. Juvenile canine drug-induced arthropathy: clinicopathological studies on articular lesions caused by oxolinic and pipemidic acids. Toxicol Appl Pharmacol. 1979;51(1):177-187 (Pubitemid 10198928)
3. American Academy of Pediatrics, Committee on Infectious Diseases. The use of systemic fluoroquinolones. Pediatrics. 2006;118(3):1287-1292
4. Rosenfeld RM, Brown L, Cannon CR, et al American Academy of Otolaryngology-Head and Neck Surgery Foundation. Clinical practice guideline: acute otitis externa. Otolaryngol Head Neck Surg. 2006;134(4 suppl):S4-S23 (Pubitemid 44389617)
5. US Food and Drug Administration. Drug approval package [ciprofloxacin]. Available at: www.accessdata.fda.gov/drugsatfda-docs/nda/2004/019537s49- 19847s27-19857s31-20780s13TOC.cfm. Accessed June 30, 2010
6. Noel GJ, Bradley JS, Kauffman RE, et al. Comparative safety profile of levofloxacin in 2523 children with a focus on four specific musculoskeletal disorders. Pediatr Infect Dis J. 2007;26(10):879-891 (Pubitemid 47494159)
7. ClinicalTrials.gov. Moxifloxacin in Pediatric Subjects With Complicated Intra-abdominal Infection (MOXIPEDIA). Available at: http://clinicaltrials.gov/ ct2/show/study/NCT01069900. Accessed June 30, 2010
8. Patterson DR. Quinolone toxicity: methods of assessment. Am J Med. 1991;91(6A):35S-37S
9. Riecke K, Lozo E, ShakiBaei M, Baumann-Wilschke I, Stahlmann R. Fluoroquinolone-induced lesions in the epiphyseal growth plates of immature rats. Presented at: Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17-20, 2000; Toronto, Ontario, Canada
10. Sendzik J, Lode H, Stahlmann R. Quinolone-induced arthropathy: an update focusing on new mechanistic and clinical data. Int J Antimicrob Agents. 2009;33(3):194-200
11. Von Keutz E, Ruhl-Fehlert C, Drommer W, Rosenbruch M. Effects of ciprofloxacin on joint cartilage in immature dogs immediately after dosing and after a 5-month treatment-free period. Arch Toxicol. 2004;78(7):418-424 (Pubitemid 39062235)
12. US Food and Drug Administration. Review and evaluation of pharmacology and toxicology data. Available at: www.accessdata. fda.gov/drugsatfda-docs/nda/ 96/020634-3.pdf. Accessed June 30, 2010
13. Sansone JM, Wilsman NJ, Leiferman EM, Conway J, Hutson P, Noonan KJ. The effect of fluoroquinolone antibiotics on growing cartilage in the lamb model. J Pediatr Orthop. 2009;29(2):189-195
14. Burkhardt JE, Walterspiel JN, Schaad UB. Quinolone arthropathy in animals versus children. Clin Infect Dis. 1997;25(5):1196-1204 (Pubitemid 27513209)
15. Chalumeau M, Tonnelier S, D'Athis P, et al Pediatric Fluoroquinolone Safety Study Investigators. Fluoroquinolone safety in pediatric patients: a prospective, multicenter, comparative cohort study in France. Pediatrics. 2003;111(6 pt 1). Available at: www.pediatrics.org/cgi/content/full/111/6/e714
16. Schaad UB, Wedgwood-Krucko J. Nalidixic acid in children: retrospective matched controlled study for cartilage toxicity. Infection. 1987;15(3):165-168 (Pubitemid 17084968)
17. Yee CL, Duffy C, Gerbino PG, Stryker S, Noel GJ. Tendon or joint disorders in children after treatment with fluoroquinolones or azithromycin. Pediatr Infect Dis J. 2002;21(6):525-529 (Pubitemid 34625833)
18. Bradley JS, Arguedas A, Blumer JL, Saez-Llorens X, Melkote R, Noel GJ. Comparative study of levofloxacin in the treatment of children with community-acquired pneumonia. Pediatr Infect Dis J. 2007;26(10):868-878 (Pubitemid 47494158)
19. Noel GJ, Blumer JL, Pichichero ME, et al. A randomized comparative study of levofloxacin versus amoxicillin/clavulanate for treatment of infants and young children with recurrent or persistent acute otitis media. Pediatr Infect Dis J. 2008;27(6):483-489
20. Hooper DC. Mechanisms of quinolone resistance. In: Hooper DC, Rubenstein EQuinolone Antimicrobial Agents. 3rd ed. Washington, DC: American Society for Microbiology Press; 2003:41-67
21. Robicsek A, Jacoby GA, Hooper DC. The worldwide emergence of plasmid-mediated quinolone resistance. Lancet Infect Dis. 2006;6(10):629-640 (Pubitemid 44427732)
22. Johnson L, Sabel A, Burman WJ, et al. Emergence of fluoroquinolone resistance in outpatient urinary Escherichia coli isolates. Am J Med. 2008;121(10):876-884
23. Qin X, Razia Y, Johnson JR, et al. Ciprofloxacin-resistant Gram-negative bacilli in the fecal microflora of children. Antimicrob Agents Chemother. 2006;50(10):3325-3329 (Pubitemid 44527505)
24. Talan DA, Krishnadasan A, Abrahamian FM, Stamm WE, Moran GJ. Prevalence and risk factor analysis of trimethoprim-sulfamethoxazole- and fluoroquinolone-resistant Escherichia coli infection among emergency department patients with pyelonephritis. Clin Infect Dis. 2008;47(9):1150-1158
25. Wang A, Yang Y, Lu Q, et al. Presence of qnr gene in Escherichia coli and Klebsiella pneumoniae resistant to ciprofloxacin isolated from pediatric patients in China. BMC Infect Dis. 2008;8:68
26. Rhomberg PR, Jones RN. Summary trends for the Meropenem Yearly Susceptibility Test Information Collection program: a 10-year experience in the United States (1999-2008). Diagn Microbiol Infect Dis. 2009;65(4):414-426
27. Morris SR, Moore DF, Hannah PB, et al. Strain typing and antimicrobial resistance of fluoroquinolone-resistant Neisseria gonorrhoeae causing a California infection outbreak. J Clin Microbiol. 2009;47(9):2944-2949
28. Wu HM, Harcourt BH, Hatcher CP, et al. Emergence of ciprofloxacin- resistant Neisseria meningitidis in North America. N Engl J Med. 2009;360(9):886-892
29. Smeesters PR, Vergison A, Junior DC, van Melderen L. Emerging fluoroquinolone-nonsusceptible group A streptococci in two different paediatric populations. Int J Antimicrob Agents. 2009;34(1):44-49
30. Yan SS, Schreckenberger PC, Zheng X, et al. An intrinsic pattern of reduced susceptibility to fluoroquinolones in pediatric isolates of Streptococcus pyogenes. Diagn Microbiol Infect Dis. 2008;62(2):205-209
31. Fedler KA, Jones RN, Sader HS, Fritsche TR. Activity of gatifloxacin tested against isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (North America, 1998-2003). Diagn Microbiol Infect Dis. 2006;55(2):157-164 (Pubitemid 43775916)
32. Adam HJ, Hoban DJ, Gin AS, Zhanel GG. Association between fluoroquinolone usage and a dramatic rise in ciprofloxacin-resistant Streptococcus pneumoniae in Canada, 1997-2006. Int J Antimicrob Agents. 2009;34(1):82-85
33. Pletz MW, McGee L, Jorgensen J, et al. Levofloxacin-resistant invasive Streptococcus pneumoniae in the United States: evidence for clonal spread and the impact of conjugate pneumococcal vaccine. Antimicrob Agents Chemother. 2004;48(9):3491-3497 (Pubitemid 39129350)
34. Pletz MW, Shergill AP, McGee L, Beall B, Whitney CG, Klugman KP. Prevalence of first-step mutants among levofloxacin-susceptible invasive isolates of Streptococcus pneumoniae in the United States. Antimicrob Agents Chemother. 2006;50(4):1561-1563
35. Morrissey I, Colclough A, Northwood J. TARGETed surveillance: susceptibility of Streptococcus pneumoniae isolated from community-acquired respiratory tract infections in 2003 to fluoroquinolones and other agents. Int J Antimicrob Agents. 2007;30(4):345-351 (Pubitemid 47361718)
36. Patel SN, Melano R, McGeer A, Green K, Low DE. Characterization of the quinolone resistant determining regions in clinical isolates of pneumococci collected in Canada. Ann Clin Microbiol Antimicrob. 2010;9:3
37. Kyaw MH, Lynfield R, Schaffner W, et al Active Bacterial Core Surveillance of the Emerging Infections Program Network. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med. 2006;354(14):1455-1463
38. Davies TA, Leibovitz E, Noel GJ, McNeeley DF, Bush K, Dagan R. Characterization and dynamics of middle ear fluid and nasopharyngeal isolates of Streptococcus pneumoniae from 12 children treated with levofloxacin. Antimicrob Agents Chemother. 2008;52(1):378-381
39. De la Campa AG, Ardanuy C, Balsalobre L, et al. Changes in fluoroquinolone-resistant Streptococcus pneumoniae after 7-valent conjugate vaccination, Spain. Emerg Infect Dis. 2009;15(6):905-911
40. Farrell DJ, Klugman KP, Pichichero M. Increased antimicrobial resistance among nonvaccine serotypes of Streptococcus pneumoniae in the pediatric population after the introduction of 7-valent pneumococcal vaccine in the United States. Pediatr Infect Dis J. 2007;26(2):123-128 (Pubitemid 46183361)
41. Fenoll A, Aguilar L, Granizo JJ, et al. Has the licensing of respiratory quinolones for adults and the 7-valent pneumococcal conjugate vaccine (PCV-7) for children had herd effects with respect to antimicrobial non-susceptibility in invasive Streptococcus pneumoniae? J Antimicrob Chemother. 2008;62(6):1430-1433
42. Mesaros N, Nordmann P, Plésiat P, et al. Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium. Clin Microbiol Infect. 2007;13(6):560-578 (Pubitemid 46730662)
43. Boyd LB, Atmar RL, Randall GL, Hamill RJ, Steffen D, Zechiedrich L. Increased fluoroquinolone resistance with time in Escherichia coli from >17,000 patients at a large county hospital as a function of culture site, age, sex, and location. BMC Infect Dis. 2008;8:4
44. Kim JY, Lautenbach E, Chu J, et al. Fluoroquinolone resistance in pediatric blood-stream infections because of Escherichia coli and Klebsiella species. Am J Infect Control. 2008;36(1):70-73 (Pubitemid 351172513)
45. Torkildsen G, Proksch JW, Shapiro A, Lynch SK, Comstock TL. Concentrations of besifloxacin, gatifloxacin, and moxifloxacin in human conjunctiva after topical ocular administration. Clin Ophthalmol. 2010;4:331-341
46. Comstock TL, Paterno MR, Usner DW, Pichichero ME. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% in children and adolescents with bacterial conjunctivitis: a post hoc, subgroup analysis of three randomized, double-masked, parallel-group, multicenter clinical trials. Paediatr Drugs. 2010;12(2):105-112
47. Wagner RS, Abelson MB, Shapiro A, Torkildsen G. Evaluation of moxifloxacin, ciprofloxacin, gatifloxacin, ofloxacin, and levofloxacin concentrations in human conjunctival tissue. Arch Ophthalmol. 2005;123(9):1282-1283 (Pubitemid 41316756)
48. Kaushik V, Malik T, Saeed SR. Interventions for acute otitis externa. Cochrane Database Syst Rev. 2010;(1):CD004740
49. Granath A, Rynnel-Dagoo B, Backheden M, Lindberg K. Tube associated otorrhea in children with recurrent acute otitis media; results of a prospective randomized study on bacteriology and topical treatment with or without systemic antibiotics. Int J Pediatr Otorhinolaryngol. 2008;72(8):1225-1233
50. Rosenfeld RM, Singer M, Wasserman JM, Stinnett SS. Systematic review of topical antimicrobial therapy for acute otitis externa. Otolaryngol Head Neck Surg. 2006;134(4 suppl):S24-S48 (Pubitemid 44389618)
51. Schwartz RH. Once-daily ofloxacin otic solution versus neomycin sulfate/polymyxin B sulfate/hydrocortisone otic suspension four times a day: a multicenter, randomized, evaluator-blinded trial to compare the efficacy, safety, and pain relief in pediatric patients with otitis externa. Curr Med Res Opin. 2006;22(9):1725-1736 (Pubitemid 44449229)
52. Chien S, Wells TG, Blumer JL, et al. Levofloxacin pharmacokinetics in children. J Clin Pharmacol. 2005;45(2):153-160 (Pubitemid 40490438)
53. Arguedas A, Dagan R, Pichichero M, et al. An open-label, double tympanocentesis study of levofloxacin therapy in children with, or at high risk for, recurrent or persistent acute otitis media. Pediatr Infect Dis J. 2006;25(12):1102-1109 (Pubitemid 44900672)
54. Richter SS, Heilmann KP, Beekmann SE, Miller NJ, Rice CL, Doern GV. The molecular epidemiology of Streptococcus pneumoniae with quinolone resistance mutations. Clin Infect Dis. 2005;40(2):225-235 (Pubitemid 40110665)
55. DailyMed. Factive (gemifloxacin mesylate) table [Oscient Pharmaceuticals] [package insert]. Available at: http://dailymed.nlm.nih.gov/dailymed/drugInfo. cfm?id=8345. Accessed June 30, 2010
56. DailyMed. Avelox (moxifloxacin hydrochloride) injection, solution; Avelox (moxifloxacin hydrochloride) tablet, film coated [Schering Plough Corporation] [package insert]. Available at: http://dailymed.nlm.nih.gov/dailymed/drugInfo. cfm?id=39708. Accessed June 30, 2010
57. DailyMed. Levaquin (levofloxacin) tablet, film coated; Levaquin (levofloxacin) solution; Levaquin (levofloxacin) injection, solution, concentrate; Levaquin (levofloxacin) injection, solution [Ortho-McNeil- Janssen Pharmaceuticals Inc] [package insert]. Available at: http://dailymed.nlm.nih. gov/dailymed/drugInfo.cfm?id=17731. Accessed June 30, 2010
58. Mandell LA, Wunderink RG, Anzueto A, et al Infectious Diseases Society of America, American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(suppl 2):S27-S72 (Pubitemid 46290553)
59. Davidson R, Cavalcanti R, Brunton JL, et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med. 2002;346(10):747-750 (Pubitemid 34983995)
60. Drusano GL, Louie A, Deziel M, Gumbo T. The crisis of resistance: identifying drug exposures to suppress amplification of resistant mutant subpopulations. Clin Infect Dis. 2006;42(4):525-532 (Pubitemid 43202526)
61. Alghasham AA, Nahata MC. Clinical use of fluoroquinolones in children. Ann Pharmacother. 2000;34(3):347-359 (Pubitemid 30133599)
62. Lynch MF, Blanton EM, Bulens S, et al. Typhoid fever in the United States, 1999-2006. JAMA. 2009;302(8):859-865
63. Leibovitz E, Janco J, Piglansky L, et al. Oral ciprofloxacin vs. intramuscular ceftriaxone as empiric treatment of acute invasive diarrhea in children. Pediatr Infect Dis J. 2000;19(11):1060-1067
64. Centers for Disease Control and Prevention. Outbreaks of multidrug-resistant Shigella sonnei gastroenteritis associated with day care centers: Kansas, Kentucky, and Missouri, 2005. MMWR Morb Mortal Wkly Rep. 2006;55(39):1068-1071
65. Shlim DR. Update in traveler's diarrhea. Infect Dis Clin North Am. 2005;19(1):137-149 (Pubitemid 40208579)
66. Engberg J, Aarestrup FM, Taylor DE, Gerner-Smidt P, Nachamkin I. Quinolone and macrolide resistance in Campylobacter jejuni and C. coli: resistance mechanisms and trends in human isolates [published correction appears in Emerg Infect Dis. 2001;7(3):491]. Emerg Infect Dis. 2001;7(1):24-34 (Pubitemid 32173330)
67. American Thoracic Society; CDC; Infectious Diseases Society of America. Treatment of tuberculosis [published correction appears in MMWR Recomm Rep. 2005;53(51):1203]. MMWR Recomm Rep. 2003;52(RR-11):1-77
68. Mitnick CD, Shin SS, Seung KJ, et al. Comprehensive treatment of extensively drugresistant tuberculosis. N Engl J Med. 2008;359(6):563-574
69. Nau R, Sörgel F, Eiffert H. Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections. Clin Microbiol Rev. 2010;Oct;23(4):858-83